financetom
Business
financetom
/
Business
/
Delhi stares at liquor shortage as private vends shut for 45 days
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Delhi stares at liquor shortage as private vends shut for 45 days
Oct 7, 2021 12:53 PM

The national capital is running low on alcohol after privately-owned liquor vends in the city were directed to shut down for 45 days from October 1. The closure comes as a result of a change in excise policy that was announced in July.

Under its new Excise Policy, the Delhi government has allocated fresh licences to private firms for 850 shops that will enter the retail business from November 17. In the transition period of nearly one-and-half months, only government-run liquor vends will remain open.

The Excise Department has also prepared to check the possibility of illicit liquor entering the city from neighbouring states due to the closure of private shops.

Also Read: Private liquor vends in Delhi to shut for over a month from October 1

On October 6, the Delhi government invited applications from hotels, clubs, motels, bars and restaurants for serving liquor at their premises.

CNBC-TV18’s Timsy Jaipuria reports that the national capital has received 215 bids for retail vends in 32 zones across the city. Delhi government has garnered Rs 8900 crore through this bidding process.

With text inputs from PTI.

Watch video for more.

(Edited by : Aditi Gautam)

First Published:Oct 7, 2021 9:53 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hong Kong regulator fines UBS $1 million over investor classification errors
Hong Kong regulator fines UBS $1 million over investor classification errors
Oct 20, 2025
HONG KONG, Oct 20 (Reuters) - Hong Kong's Security Regulator (SFC) said on Monday that it had reprimanded Swiss bank UBS AG and fined it HK$8 million ($1.03 million) for misclassifying its clients' professional investor status for more than 12 years. A total of 560 joint accounts booked or managed in Hong Kong by the bank were misclassified, the regulator...
Exelixis Reports Detailed Results of Phase 3 Trial of Cancer Combo Treatment; Shares Down Pre-Bell
Exelixis Reports Detailed Results of Phase 3 Trial of Cancer Combo Treatment; Shares Down Pre-Bell
Oct 20, 2025
05:38 AM EDT, 10/20/2025 (MT Newswires) -- Exelixis ( EXEL ) on Monday reported detailed results of a phase 3 trial of zanzalintinib in combination with atezolizumab versus regorafenib in patients with previously treated non-microsatellite instability-high metastatic colorectal cancer. The median overall survival in the intention-to-treat population was 10.9 months with the combination versus 9.4 months with regorafenib at a...
Russian titanium producer VSMPO-AVISMA to cut working week for some staff
Russian titanium producer VSMPO-AVISMA to cut working week for some staff
Oct 20, 2025
MOSCOW, Oct 20 (Reuters) - Russia's VSMPO-AVISMA , the world's biggest producer of titanium, said on Monday that it plans to switch to a four-day working week for some employees not directly involved in production. It is planned to transfer some employees who are not involved in key production processes, mainly administrative staff, to a four-day working week, the company...
Summit Says Ivonescimab Demonstrates 'Significant' Improvement in Progression-Free Survival in Phase 3 Lung Cancer Trial
Summit Says Ivonescimab Demonstrates 'Significant' Improvement in Progression-Free Survival in Phase 3 Lung Cancer Trial
Oct 20, 2025
05:19 AM EDT, 10/20/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Sunday that its ivonescimab product candidate, in combination with chemotherapy, demonstrated a statistically significant improvement in progression-free survival compared with tislelizumab plus chemotherapy in a phase 3 study of the combination therapy in advanced squamous non-small cell lung cancer. The company said the findings were based on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved